Efficacy of novel drug proven in MDD study
European Pharmaceutical Review
JULY 19, 2023
The data “are compelling, particularly the significant improvements observed in both depressive and anhedonic symptoms,” stated Dr Roger S McIntyre, FRCPC, Professor of psychiatry and pharmacology, University of Toronto and Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.
Let's personalize your content